GASTROENTEROLOGY

DICETEL® (pinaverium bromide)
DICETEL® (pinaverium bromide) is one of Solvay Pharmaceuticals’ drugs for irritable bowel syndrome and the first available drug with a specific effect on calcium channels. It is now used by millions of patients. Irritable bowel syndrome is a chronic disease that affects at least 10% of the population. Only half visit a doctor for these symptoms. IBS is the second most common cause of work and school absenteeism, the first being the common cold. The pain associated with irritable bowel syndrome can be so severe that sufferers cannot function properly. DICETEL® contributes to Solvay Pharmaceuticals’ leading position in the market of gastrointestinal spasmolytics.

generic name
brandnames
product description
indications
description of indications
worldwide availability
date and country of first launch
average dosages
links

generic name
pinaverium bromide
[back to top]

brandnames
DICETEL®, ELDICET®
[back to top]

product description
DICETEL® (pinaverium bromide) is a calcium antagonist. It has a highly selective spasm-reducing action in the gastrointestinal tract.
[back to top]

indications
Irritable bowel syndrome
[back to top]

description of indications
Irritable Bowel Syndrome
DICETEL® (pinaverium bromide) is used for the symptomatic treatment of abdominal pain, bowel disturbances and intestinal discomfort related to irritable bowel syndrome (IBS). IBS is caused by a hypersensitivity of nerves in the bowels. This hypersensitivity causes the bowels to contract abnormally. Irritable bowel syndrome causes pain, bloatedness, diarrhea and constipation. Ten to twenty percent of all adults experience symptoms of IBS.
[back to top]

worldwide availability
DICETEL® (pinaverium bromide) is marketed in several major countries, including Canada and France
[back to top]

date and country of first launch
1975
[back to top]

average dosages
150 mg to 300 mg per day ( in adults).
[back to top]

Links
http://www.solvay-ibs.com
[back to top]

Leave a comment

Your email address will not be published. Required fields are marked *